Morgan Stanley’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,396,216
| Closed | -$24.5M | – | 8399 |
|
|
2021
Q3 | $24.5M | Buy |
1,396,216
+1,073,340
| +332% | +$12.5M | ﹤0.01% | 1876 |
|
|
2021
Q2 | $3.13M | Buy |
322,876
+10,532
| +3% | +$99.1K | ﹤0.01% | 4245 |
|
|
2021
Q1 | $3.35M | Buy |
312,344
+31,405
| +11% | +$388K | ﹤0.01% | 3823 |
|
|
2020
Q4 | $4.13M | Buy |
280,939
+24,658
| +10% | +$356K | ﹤0.01% | 3466 |
|
|
2020
Q3 | $3.64M | Buy |
256,281
+94,736
| +59% | +$945K | ﹤0.01% | 3028 |
|
|
2020
Q2 | $1.31M | Sell |
161,545
-27,381
| -14% | -$169K | ﹤0.01% | 3954 |
|
|
2020
Q1 | $764K | Sell |
188,926
-1,681,078
| -90% | -$6.35M | ﹤0.01% | 4129 |
|
|
2019
Q4 | $1.93M | Buy |
1,870,004
+709,906
| +61% | +$271K | ﹤0.01% | 4075 |
|
|
2019
Q3 | $356K | Buy |
1,160,098
+114,400
| +11% | +$38.7K | ﹤0.01% | 4840 |
|
|
2019
Q2 | $343K | Buy |
1,045,698
+275,800
| +36% | +$142K | ﹤0.01% | 4787 |
|
|
2019
Q1 | $508K | Buy |
769,898
+246,743
| +47% | +$302K | ﹤0.01% | 4541 |
|
|
2018
Q4 | $894K | Buy |
523,155
+166,500
| +47% | +$500K | ﹤0.01% | 4360 |
|
|
2018
Q3 | $2.07M | Buy |
356,655
+71,860
| +25% | +$405K | ﹤0.01% | 3970 |
|
|
2018
Q2 | $1.71M | Buy |
284,795
+58,900
| +26% | +$375K | ﹤0.01% | 4222 |
|
|
2018
Q1 | $1.63M | Buy |
225,895
+65,040
| +40% | +$493K | ﹤0.01% | 4181 |
|
|
2017
Q4 | $1.17M | Buy |
160,855
+99,985
| +164% | +$828K | ﹤0.01% | 4438 |
|
|
2017
Q3 | $314K | Buy |
60,870
+54,100
| +799% | +$254K | ﹤0.01% | 5137 |
|
|
2017
Q2 | $29K | Buy |
6,770
+6,070
| +867% | +$33.6K | ﹤0.01% | 6006 |
|
|
2017
Q1 | $4K | Buy |
+700
| New | +$4.1K | ﹤0.01% | 6398 |
|
|
2016
Q4 | – | Sell |
-400
| Closed | -$6K | – | 6598 |
|
|
2016
Q3 | $6K | Buy |
+400
| New | +$4.61K | ﹤0.01% | 6215 |
|
|
2016
Q2 | – | Sell |
-4,889
| Closed | -$45K | – | 6733 |
|
|
2016
Q1 | $45K | Buy |
4,889
+3,977
| +436% | +$33.5K | ﹤0.01% | 5655 |
|
|
2015
Q4 | $11K | Buy |
912
+273
| +43% | +$3.8K | ﹤0.01% | 6218 |
|
|
2015
Q3 | $8K | Hold |
639
| – | – | ﹤0.01% | 6305 |
|
|
2015
Q2 | $14K | Sell |
639
-611
| -49% | -$13.9K | ﹤0.01% | 6227 |
|
|
2015
Q1 | $25K | Buy |
+1,250
| New | +$18.4K | ﹤0.01% | 5994 |
|
Other funds holding TRIL
Morgan Stanley's TRIL Position: Q4 2021 in Review
Morgan Stanley sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,396,216 shares — an estimated $24.5M sold.
Morgan Stanley first reported a position in TRIL in Q1 2015 and held it in 25 quarters. The position peaked at $24.5M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Morgan Stanley reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Morgan Stanley sold 1,396,216 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $24.5M.
- Morgan Stanley first reported a position in Trillium Therapeutics Inc. in Q1 2015 and held it in 25 quarters.
- Morgan Stanley's Trillium Therapeutics Inc. position peaked at $24.5M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Morgan Stanley's 13F filing for Q4 2021, filed 14 Feb 2022.